Showing results (301-310 of 328) with videos related to
Sort By:
Pageof 33
Nature Communications|November 19, 2021
Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammationGrigory Ryzhakov, Hannah Almuttaqi, Alastair L Corbin, et al.Thescientificworldjournal|June 14, 2003
Response of Acala cotton to nitrogen rates in the San Joaquin Valley of CaliforniaR B Hutmacher, R L Travis, R L Nichols, et al.Scientific Reports|April 28, 2016
Accumulation of isolevuglandin-modified protein in normal and fibrotic lungStacey Mont, Sean S Davies, L Jackson Roberts Second, et al.Journal of Occupational and Environmental Medicine|July 3, 2014
ACOEM practice guidelines: opioids and safety-sensitive workKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.Journal of Crohn'S & Colitis|May 23, 2018
Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow TransplantationCharlotte K Brierley, Cristina Castilla-Llorente, Myriam Labopin, et al.The Lancet. Gastroenterology & Hepatology|March 24, 2018
Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trialJasper L A Vleugels, Matt D Rutter, Krish Ragunath, et al.Journal of Crohn'S & Colitis|September 12, 2018
Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative ColitisJasper L A Vleugels, Mathew D Rutter, Krish Ragunath, et al.Journal of Occupational and Environmental Medicine|November 22, 2014
ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative painKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.BMJ Open|May 1, 2015
Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trialH E Campbell, E A Stokes, D Bargo, et al.Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.Pageof 33